argenx Acquires Forte Biosciences for $2.2 Billion to Expand Immunology Portfolio Beyond Vyvgart Into Inflammatory Dermatology

The Quick Take

• argenx SE (ARGX) agreed to acquire Forte Biosciences (FBRX) for approximately $2.2 billion, expanding its immunology pipeline into inflammatory skin disease treatments
• Forte's lead asset targets atopic dermatitis and related inflammatory conditions where argenx sees synergies with its FcRn inhibitor platform
• The deal comes as argenx accelerates geographic and indication expansion of efgartigimod (Vyvgart) while adding a complementary immunology modality

argenx SE (NASDAQ: ARGX), the Belgian immunology-focused biopharma company, announced an agreement to acquire Forte Biosciences (NASDAQ: FBRX) for approximately $2.2 billion, significantly expanding its immunology pipeline into inflammatory dermatology. The deal follows argenx's commercial success with efgartigimod alfa (Vyvgart), its approved FcRn inhibitor for generalized myasthenia gravis and other autoimmune conditions. Forte Biosciences develops next-generation treatments for inflammatory skin conditions including atopic dermatitis — a large and growing indication where argenx sees strategic fit with its immunology mechanistic expertise. Multiple news sources confirmed the deal terms across both US and European financial media.

The $2.2 billion valuation for Forte represents a substantial premium to FBRX's pre-announcement trading price, with Forte shares surging 39.2% on the deal announcement as arbitrageurs and growth investors rerated the small-cap biotech to near the acquisition price. For argenx, the strategic rationale is clear: efgartigimod's FcRn mechanism is broadly applicable across IgG-mediated autoimmune diseases, and adding a complementary dermatology asset with a differentiated mechanism creates pipeline diversification against Vyvgart's concentrated indication exposure. The deal intensifies argenx's competition with AstraZeneca (CGRP inhibitors), AbbVie (Rinvoq, Skyrizi), and Regeneron/Sanofi (Dupixent) in the broader immunology market.

Key watchpoints post-deal include argenx's integration timeline for Forte's clinical programs and whether Forte's lead asset can be accelerated through regulatory approval using argenx's immunology clinical infrastructure. The critical signal will be any regulatory guidance on a fast-track or priority review designation for Forte's lead inflammatory dermatology program. The macro variable: the US payer landscape for dermatology biologics — characterized by tight formulary restrictions and step-therapy requirements by major PBMs — will determine how quickly a new entrant could achieve commercial uptake against established Dupixent, even with a differentiated mechanism.

Synthesized from 5 sources.